bluereg and the brexit



On 23 June 2016 the UK voted to leave the EU. Negotiation continues in 2018 with the end of the Article 50 negotiation period, set for 29 March 2019, fast approaching. Various agreements for the terms of this exit, alongside the long term implications for many industries including the Pharmaceutical Industry, are still to be determined.

The European Commission, EMA, MHRA, National Health Authorities and trade associations have been issuing statements and guidance on Brexit in relation to medicine and device regulation.

BlueReg is monitoring the situation closely and provides regular updates here and on our LinkedIn Page where you can follow us.


Discover our last white Paper

Learn more